DUBLIN–(BUSINESS WIRE)–The “TissueGen Inc – Product Pipeline Analysis, 2019 Update” company profile has been added to ResearchAndMarkets.com’s offering.
Summary
TissueGen Inc (TissueGen) is a medical device company that develops fiber for advanced drug delivery, nerve regeneration and tissue engineering. The company’s products comprise of pharmaceutical fibers and growth factor fibers. It offers pharmaceutical fibers and growth factor fibers. TissueGen’s products are used in sciatic nerve repair, peripheral nerve regeneration, spinal cord repair, dermal wound healing and treatment of retinal disease among others. The company’s research and development department designs several fiber-based solutions which include anti-fibrillation devices, cardiovascular stents, nicotine-induced angiogenesis, ocular drug delivery and others. TissueGen is headquartered in Dallas, Texas, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company TissueGen Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Key Topics Covered:
- TissueGen Inc Company Overview
- TissueGen Inc Company Snapshot
- TissueGen Inc Pipeline Products and Ongoing Clinical Trials Overview
- TissueGen Inc – Pipeline Analysis Overview
- TissueGen Inc – Key Facts
- TissueGen Inc – Major Products and Services
- TissueGen Inc Pipeline Products by Development Stage
- TissueGen Inc Pipeline Products Overview
- Anti-Fibrillation Devices
- Archer Stent
- Cardiovascular Stent
- ELUTE Fiber – Diabetic Retinopathy
- ELUTE Fiber – Nicotine Induced Angiogenesis
- ELUTE Fiber – Peripheral Nerve Regeneration Scaffold
- ELUTE Fiber – Retinal Angiogenesis
- ELUTE Fiber – Smart Suture
- ELUTE Fiber – Spinal Cord Injury Repair
- ELUTE Fiber – Urological Stent
- TissueGen Inc – Key Competitors
- TissueGen Inc – Key Employees
- TissueGen Inc – Locations And Subsidiaries
- Head Office
- Recent Developments
- TissueGen Inc, Recent Developments
- Apr 16, 2018: Tissuegen Founder And Cso Dr. Kevin Nelson To Present Enabling The Next Generation Of Drug Delivery Through Implantable Medical Devices Session At Biomedevice Boston
- Jan 17, 2018: TissueGen to Feature ELUTE Fiber for Advanced Drug Delivery, Nerve Regeneration and Tissue Engineering at MDM West
- Sep 26, 2017: Edward Parent Appointed Director of Quality Assurance at TissueGen
- Jun 05, 2017: Tissuegen to Highlight Elute Fiber for Advanced Drug Delivery, Nerve Regeneration and Tissue Engineering at MD&M East
- Apr 19, 2017: TissueGen appoints New Faces for Growing Sales Team
- Feb 27, 2017: TissueGen appoints new scientific advisory board member
- Feb 27, 2017: Dr. Lisa A. Fortier Joins TissueGen’s Scientific Advisory Board
- Nov 07, 2016: TissueGen to Showcase ELUTE Fiber for Nerve Regeneration, Tissue Engineering and Advanced Drug Delivery at Neuroscience 2016
- Mar 28, 2016: TissueGen Announces ISO13485:2003 Certification and Record Growth Driven by ELUTE Fiber
- Dec 15, 2015: TissueGen’s New ISO Class 7 Facility Supports FDA cGMP Drug Product Manufacturing
- Appendix
- Methodology
- About the Author
- Contact Us
- Disclaimer
Companies Mentioned
- Shionogi Inc
- Nexgen Pharma Inc
- Mission Pharmacal Company
- Delpor Inc
For more information about this company profile visit https://www.researchandmarkets.com/r/szomgb
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900